Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.32 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664678 | 0.89 | ADRA1A (0.48) | ADRA1AALDH1A1HPGDWDR5NSD2 | |
| SCHEMBL3665381 | 0.88 | ADRA1A (0.44) | ADRA1AALDH1A1LMNAHPGDHIF1A | |
| Hydrochloric Acid SCHEMBL4093442 | 0.88 | ADRA1A (0.47) | ADRA1AALDH1A1HPGDWDR5NSD2 | |
| SCHEMBL3660427 | 0.86 | KDM4E (0.35) | ADRA1AALDH1A1LMNAWDR5RAB9A | |
| Hydrochloric Acid SCHEMBL4089608 | 0.85 | KDM4E (0.35) | ADRA1AALDH1A1LMNAWDR5RAB9A | |
| SCHEMBL3667282 | 0.84 | ADRA1A (0.35) | ADRA1AHIF1AWDR5RIPK1HDAC2 | |
| SCHEMBL3664098 | 0.79 | ADRA1A (0.54) | ADRA1AALDH1A1LMNAGAARAB9A | |
| SCHEMBL24066066 | 0.79 | HCAR2 (0.43) | ADRA1AHCRTR1HCRTR2RIPK1 | |
| SCHEMBL4029675 | 0.79 | ADRA1A (0.41) | ADRA1AALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21033253 | 0.79 | HCAR2 (0.43) | ADRA1AHCRTR1HCRTR2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | STAT1 4691/4885FGFR4 1828/4885ADRA1A 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.